Atossa Therapeutics Files 8-K

Ticker: ATOS · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1488039

Sentiment: neutral

Topics: sec-filing, 8-k, corporate-update

Related Tickers: ATOS

TL;DR

ATOS filed an 8-K, looks like standard procedure, no major news.

AI Summary

On September 26, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or disclosures beyond routine reporting requirements as of that date. The company is incorporated in Delaware and headquartered in Seattle, Washington.

Why It Matters

This 8-K filing serves as a notification to the SEC and investors about significant corporate events. As this filing appears routine, it suggests no immediate major developments for Atossa Therapeutics.

Risk Assessment

Risk Level: low — The filing is a standard 8-K current report, indicating no specific material events or disclosures that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Atossa Therapeutics?

The primary purpose of this 8-K filing is to report significant corporate events or material information that is not otherwise required to be reported on a periodic basis, as per SEC regulations.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on September 26, 2025.

Where are Atossa Therapeutics' principal executive offices located?

Atossa Therapeutics' principal executive offices are located at 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.

What is Atossa Therapeutics' state of incorporation?

Atossa Therapeutics, Inc. is incorporated in Delaware.

Does this 8-K filing disclose any specific new material events?

Based on the provided text, this 8-K filing appears to be a standard current report and does not explicitly detail any specific new material events or disclosures beyond the filing itself.

Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-26 17:12:32

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On September 26, 2025, Atossa Therapeutics, Inc. (the "Company") made available an updated corporate presentation, which is attached to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing .

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Corporate Presentation, dated September 26, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: September 26, 2025 By: /s/ Steven C. Quay Steven C. Quay, M.D., Ph.D. Chairman, President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing